Your browser doesn't support javascript.
loading
Antibody response patterns in chikungunya febrile phase predict protection versus progression to chronic arthritis.
Nayak, Kaustuv; Jain, Vineet; Kaur, Manpreet; Khan, Naushad; Gottimukkala, Kamalvishnu; Aggarwal, Charu; Sagar, Rohit; Gupta, Shipra; Rai, Ramesh Chandra; Dixit, Kritika; Islamuddin, Mohammad; Khan, Wajihul Hasan; Verma, Anil; Maheshwari, Deepti; Chawla, Yadya M; Reddy, Elluri Seetharami; Panda, Harekrushna; Sharma, Pragati; Bhatnagar, Priya; Singh, Prabhat; Raghavendhar B, Siva; Patel, Ashok Kumar; Ratageri, Vinod H; Chandele, Anmol; Ray, Pratima; Murali-Krishna, Kaja.
Afiliação
  • Nayak K; ICGEB-Emory Vaccine Centre, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg, New Delhi, India.
  • Jain V; Department of Medicine, Hamdard Institute of Medical Sciences and Research (HIMSAR), Jamia Hamdard, New Delhi, India.
  • Kaur M; ICGEB-Emory Vaccine Centre, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg, New Delhi, India.
  • Khan N; Department of Biotechnology, School of Chemical & Life Sciences, Jamia Hamdard, New Delhi, India.
  • Gottimukkala K; ICGEB-Emory Vaccine Centre, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg, New Delhi, India.
  • Aggarwal C; ICGEB-Emory Vaccine Centre, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg, New Delhi, India.
  • Sagar R; Department of Biotechnology, School of Chemical & Life Sciences, Jamia Hamdard, New Delhi, India.
  • Gupta S; Department of Biotechnology, School of Chemical & Life Sciences, Jamia Hamdard, New Delhi, India.
  • Rai RC; ICGEB-Emory Vaccine Centre, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg, New Delhi, India.
  • Dixit K; ICGEB-Emory Vaccine Centre, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg, New Delhi, India.
  • Islamuddin M; Department of Biotechnology, School of Chemical & Life Sciences, Jamia Hamdard, New Delhi, India.
  • Khan WH; Department of Biotechnology, School of Chemical & Life Sciences, Jamia Hamdard, New Delhi, India.
  • Verma A; Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
  • Maheshwari D; ICGEB-Emory Vaccine Centre, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg, New Delhi, India.
  • Chawla YM; ICGEB-Emory Vaccine Centre, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg, New Delhi, India.
  • Reddy ES; ICGEB-Emory Vaccine Centre, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg, New Delhi, India.
  • Panda H; ICGEB-Emory Vaccine Centre, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg, New Delhi, India.
  • Sharma P; ICGEB-Emory Vaccine Centre, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg, New Delhi, India.
  • Bhatnagar P; ICGEB-Emory Vaccine Centre, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg, New Delhi, India.
  • Singh P; ICGEB-Emory Vaccine Centre, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg, New Delhi, India.
  • Raghavendhar B S; Kusuma School of Biological Sciences, Indian Institute of Technology (IIT), New Delhi, India.
  • Patel AK; Kusuma School of Biological Sciences, Indian Institute of Technology (IIT), New Delhi, India.
  • Ratageri VH; Department of Pediatrics, Karnataka Institute of Medical Sciences (KIMS), Hubli, Karnataka, India.
  • Chandele A; ICGEB-Emory Vaccine Centre, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg, New Delhi, India.
  • Ray P; Department of Biotechnology, School of Chemical & Life Sciences, Jamia Hamdard, New Delhi, India.
  • Murali-Krishna K; ICGEB-Emory Vaccine Centre, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg, New Delhi, India.
JCI Insight ; 5(7)2020 04 09.
Article em En | MEDLINE | ID: mdl-32155134
ABSTRACT
Chikungunya virus (CHIKV) infection causes acute febrile illness in humans, and some of these individuals develop a debilitating chronic arthritis that can persist for months to years for reasons that remain poorly understood. In this study from India, we characterized antibody response patterns in febrile chikungunya patients and further assessed the association of these initial febrile-phase antibody response patterns with protection versus progression to developing chronic arthritis. We found 5 distinct patterns of the antibody responses in the febrile phase no CHIKV binding or neutralizing (NT) antibodies but PCR positive, IgM alone with no NT activity, IgM alone with NT activity, IgM and IgG without NT activity, and IgM and IgG with NT activity. A 20-month follow-up showed that appearance of NT activity regardless of antibody isotype or appearance of IgG regardless of NT activity during the initial febrile phase was associated with a robust protection against developing chronic arthritis in the future. These findings, while providing potentially novel insights on correlates of protective immunity against chikungunya-induced chronic arthritis, suggest that qualitative differences in the antibody response patterns that have evolved during the febrile phase can serve as biomarkers that allow prediction of protection or progression to chronic arthritis in the future.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Artrite / Imunoglobulina G / Imunoglobulina M / Vírus Chikungunya / Febre de Chikungunya / Anticorpos Antivirais / Formação de Anticorpos Tipo de estudo: Clinical_trials / Prognostic_studies / Qualitative_research / Risk_factors_studies Limite: Humans Idioma: En Revista: JCI Insight Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Índia

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Artrite / Imunoglobulina G / Imunoglobulina M / Vírus Chikungunya / Febre de Chikungunya / Anticorpos Antivirais / Formação de Anticorpos Tipo de estudo: Clinical_trials / Prognostic_studies / Qualitative_research / Risk_factors_studies Limite: Humans Idioma: En Revista: JCI Insight Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Índia